Supplements maker Prenetics' Q1 revenue surges on IM8 growth, raises outlook

Prenetics Global

10/06/2026 13:46

Overview
Consumer health sciences firm's Q1 2026 revenue rose sharply yr/yr, led by IM8 brand growth
Company raised full-year 2026 IM8 revenue guidance and projects strong Q2 sequential growth
Prenetics fully divested digital assets for $41.3 mln and repurchased $19 mln in shares

Outlook
Prenetics raises full-year 2026 IM8 revenue guidance to $190 mln-$210 mln from $180 mln-$200 mln
Company expects Q2 2026 revenue of $46 mln-$48 mln, with IM8 contributing $44 mln-$46 mln
Prenetics plans three new IM8 SKUs for Q4 2026 in hydration, creatine and kids’ gummies

Result Drivers
IM8 GROWTH - IM8 brand revenue rose 23% sequentially and nearly 6x yr/yr, driven by increased consumer engagement and international expansion
GROSS MARGIN EXPANSION - Gross margin for IM8 rose to 64% from 60% in Q4 2025, attributed to manufacturing efficiencies, renegotiated supplier terms, favorable product mix, and improved logistics
SUBSCRIPTION TRANSITION - Shift to quarterly subscription plans increased average order value and servings per order, though total customer orders declined modestly

Company press release: ID:nGNXbbGBtn

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
 
-$1.36
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Prenetics Global Ltd is $30.00, about 43.3% above its June 9 closing price of $20.93

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)